Article info

Original research
Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma

Authors

  1. Correspondence to Professor Walter J Storkus; storkuswj{at}upmc.edu
View Full Text

Citation

Storkus WJ, Maurer D, Lin Y, et al
Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma

Publication history

  • Accepted October 17, 2021
  • First published November 15, 2021.
Online issue publication 
November 15, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.